Brian E. Cairns
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Brian E. Cairns has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Lars Arendt-Nielsen
Center for Neuroplasticity and Pain (CNAP), Sensory-Motor Interaction (SMI) Center, Department of Health Science and Technology, Faculty of Medicine, Aalborg University, DK-9220 Aalborg, Denmark
9 shared publications Peter Svensson
6 shared publicationsBarry J Sessle
5 shared publications- Eduardo Castrillon
Section for Orofacial Pain and Jaw Function, Department of Dentistry and Oral Health Aarhus University Aarhus Denmark
5 shared publications - Kelun Wang
Center for Sensory-Motor Interaction, Orofacial Pain Laboratory, Aalborg University, Fredrik Bajers Vej 7 D-3, DK-9220 Aalborg, Denmark
5 shared publications - Peter Svensson
Section of Orofacial Pain and Jaw Function, Department of Dentistry and Oral Health, Aarhus University, 8000 Aarhus, Denmark
5 shared publications
Latest Publications
- 1 January 2013
- Published by Springer Nature
- p. 2261-2264
Nociceptors in the Orofacial Region (Temporomandibular Joint and Masseter Muscle)
- 1 January 2013
- Published by Springer Nature
- p. 2261-2264
Nociceptors in the Orofacial Region (Temporomandibular Joint and Masseter Muscle)
- 1 January 2012
- Vol. 15 (2) , 89-97
Expression of NMDA and oestrogen receptors by trigeminal ganglion neurons that innervate the rat temporalis muscle.
To assess whether N-methyl-D-aspartate (NMDA) receptor (NR) or oestrogen receptor (OR) expression plays a role in the differences that temporalis muscle afferent fibres are less sensitive to peripheral receptor activation than masseter muscle afferent fibres and do not exhibit sex-related differences in NMDA-evoked discharge. Immunohistochemical techniques were used to examine the expression of NR1, 2A, and 2B subunits of the NMDA receptor in male and female rats and the co-expression of NR2B subunits with ORs in female rats by trigeminal ganglion neurons that innervate the temporalis muscle. In vivo electrophysiological recording methods were employed to assess the response of afferent fibres to injection of NMDA into the temporalis muscle in female rats. Approximately 20% of temporalis ganglion neurons expressed NR1, NR2A and NR2B subunits, respectively, and there was no sex-related difference in the expression of these subunits. In female rats, both ORα and ORß receptors were identified in the trigeminal ganglion by Western blot. ORs were found on the majority (~80%) of temporalis ganglion neurons that expressed NR2B subunits. A significant positive correlation between blood oestrogen concentration and NMDA-evoked afferent discharge was identified. The absence of sex-related differences in NMDA receptor expression may account for the lack of sex-related differences in NMDA-evoked temporalis afferent discharge. The association of elevated oestrogen concentration with increased afferent response to NMDA and the co-expression of NRs and ORs in temporalis ganglion neurons suggest that sensory input from the temporalis muscle may be modulated by oestrogenic tone.
- 1 January 2012
- Vol. 15 (2) , 89-97
Expression of NMDA and oestrogen receptors by trigeminal ganglion neurons that innervate the rat temporalis muscle.
To assess whether N-methyl-D-aspartate (NMDA) receptor (NR) or oestrogen receptor (OR) expression plays a role in the differences that temporalis muscle afferent fibres are less sensitive to peripheral receptor activation than masseter muscle afferent fibres and do not exhibit sex-related differences in NMDA-evoked discharge. Immunohistochemical techniques were used to examine the expression of NR1, 2A, and 2B subunits of the NMDA receptor in male and female rats and the co-expression of NR2B subunits with ORs in female rats by trigeminal ganglion neurons that innervate the temporalis muscle. In vivo electrophysiological recording methods were employed to assess the response of afferent fibres to injection of NMDA into the temporalis muscle in female rats. Approximately 20% of temporalis ganglion neurons expressed NR1, NR2A and NR2B subunits, respectively, and there was no sex-related difference in the expression of these subunits. In female rats, both ORα and ORß receptors were identified in the trigeminal ganglion by Western blot. ORs were found on the majority (~80%) of temporalis ganglion neurons that expressed NR2B subunits. A significant positive correlation between blood oestrogen concentration and NMDA-evoked afferent discharge was identified. The absence of sex-related differences in NMDA receptor expression may account for the lack of sex-related differences in NMDA-evoked temporalis afferent discharge. The association of elevated oestrogen concentration with increased afferent response to NMDA and the co-expression of NRs and ORs in temporalis ganglion neurons suggest that sensory input from the temporalis muscle may be modulated by oestrogenic tone.
- 1 January 2012
- Vol. 26 (3) , 191-205
Experimental stressors alter hypertonic saline-evoked masseter muscle pain and autonomic response.
To test in a randomized controlled trial, if hypertonic saline (HS)-evoked pain and autonomic function are modulated by either a cold pressor test (CPT) or mental arithmetic stress induced by a paced auditory serial addition task (PASAT). Fourteen healthy women participated in three sessions. Pain was induced by two 5% HS infusions (5 minutes each, 30 minutes apart) infused into the masseter muscle. During the second HS infusion, pain was modulated by PASAT, CPT, or control (HS alone). HS-evoked pain intensity was scored on a 0 to 10 numeric rating scale (NRS). Heart rate variability (HRV) and hemodynamic measures were recorded noninvasively (Task Force Monitor). Data were analyzed using repeated measurements ANOVAs and Spearman correlation analysis. HS-evoked pain was significantly and similarly reduced by both PASAT (30.8 ± 27.6%; P < .001) and CPT (35.8 ± 26.6%; P < .001) compared with the control session (9.0 ± 30.5%; P > .05). PASAT and CPT increased the heart rate compared with control (P <.001). CPT reduced measures of vagal activity: Root mean square successive difference, high-frequency (HF) power, and coefficient of HF component variance compared with an internal control, ie, the first HS infusion (P < .05), while PASAT did not alter any of these HRV measures (P > .05). CPT and PASAT reduced HS-evoked masseter muscle pain and altered the autonomic response. The increase in heart rate following CPT and PASAT may be caused by different mechanisms. CPT reduced measures of efferent cardiac vagal (parasympathetic) activity, while the PASAT-induced increase in heart rate, but unchanged HRV, may suggest neurohumoral activation.
- 1 January 2012
- Vol. 26 (3) , 191-205
Experimental stressors alter hypertonic saline-evoked masseter muscle pain and autonomic response.
To test in a randomized controlled trial, if hypertonic saline (HS)-evoked pain and autonomic function are modulated by either a cold pressor test (CPT) or mental arithmetic stress induced by a paced auditory serial addition task (PASAT). Fourteen healthy women participated in three sessions. Pain was induced by two 5% HS infusions (5 minutes each, 30 minutes apart) infused into the masseter muscle. During the second HS infusion, pain was modulated by PASAT, CPT, or control (HS alone). HS-evoked pain intensity was scored on a 0 to 10 numeric rating scale (NRS). Heart rate variability (HRV) and hemodynamic measures were recorded noninvasively (Task Force Monitor). Data were analyzed using repeated measurements ANOVAs and Spearman correlation analysis. HS-evoked pain was significantly and similarly reduced by both PASAT (30.8 ± 27.6%; P < .001) and CPT (35.8 ± 26.6%; P < .001) compared with the control session (9.0 ± 30.5%; P > .05). PASAT and CPT increased the heart rate compared with control (P <.001). CPT reduced measures of vagal activity: Root mean square successive difference, high-frequency (HF) power, and coefficient of HF component variance compared with an internal control, ie, the first HS infusion (P < .05), while PASAT did not alter any of these HRV measures (P > .05). CPT and PASAT reduced HS-evoked masseter muscle pain and altered the autonomic response. The increase in heart rate following CPT and PASAT may be caused by different mechanisms. CPT reduced measures of efferent cardiac vagal (parasympathetic) activity, while the PASAT-induced increase in heart rate, but unchanged HRV, may suggest neurohumoral activation.
- Top Cited Papers
- 11 May 2010
- Published by Wiley in Journal of Oral Rehabilitation
- Vol. 37 (6) , 391-410
Pathophysiology of TMD pain - basic mechanisms and their implications for pharmacotherapy
This article discusses the pathophysiology of temporomandibular disorders (TMD)-related pain and its treatment with analgesic drugs. Temporomandibular disorders are comprised of a group of conditions that result in temporomandibular joint pain (arthralgia, arthritis) and/or masticatory muscle pain (myofascial TMD). In at least some patients with TMD, a peripheral mechanism contributes to this pain. However, there is often a poor correlation between the severity of TMD-related pain complaints and evidence of definitive tissue pathology. This has led to the concept that pain in some patients with TMD may result from altered central nervous system pain processing and further that this altered pain processing may be attributable to specific genes that are heritable. Psychosocial stressors are also thought to contribute to the development of TMD-related pain, particularly masticatory muscle pain. Finally, substantially more women suffer from TMD than men. Although there are arguably multiple reasons for sex-related differences in the prevalence of TMD, one candidate for the increased occurrence of this disorder in women has been suggested to be the female sex hormone oestrogen. Analgesic drugs are an integral part of the primary treatment for TMD-related pain and dysfunction with more that 90% of treatment recommendations involving use of medications. The most commonly used agents include non-steroidal anti-inflammatory drugs, corticosteroids, muscle relaxants, anxiolytics, opiates and tricyclic antidepressants, however, evidence in support of the effectiveness of these drugs is lacking. Continued research into the pathophysiology of TMD-related pain and the effectiveness of analgesic treatments for this pain is required.
- 11 May 2010
- Published by Wiley in Journal of Oral Rehabilitation
- Vol. 37 (6) , 391-410
Top Cited PapersPathophysiology of TMD pain - basic mechanisms and their implications for pharmacotherapy
This article discusses the pathophysiology of temporomandibular disorders (TMD)-related pain and its treatment with analgesic drugs. Temporomandibular disorders are comprised of a group of conditions that result in temporomandibular joint pain (arthralgia, arthritis) and/or masticatory muscle pain (myofascial TMD). In at least some patients with TMD, a peripheral mechanism contributes to this pain. However, there is often a poor correlation between the severity of TMD-related pain complaints and evidence of definitive tissue pathology. This has led to the concept that pain in some patients with TMD may result from altered central nervous system pain processing and further that this altered pain processing may be attributable to specific genes that are heritable. Psychosocial stressors are also thought to contribute to the development of TMD-related pain, particularly masticatory muscle pain. Finally, substantially more women suffer from TMD than men. Although there are arguably multiple reasons for sex-related differences in the prevalence of TMD, one candidate for the increased occurrence of this disorder in women has been suggested to be the female sex hormone oestrogen. Analgesic drugs are an integral part of the primary treatment for TMD-related pain and dysfunction with more that 90% of treatment recommendations involving use of medications. The most commonly used agents include non-steroidal anti-inflammatory drugs, corticosteroids, muscle relaxants, anxiolytics, opiates and tricyclic antidepressants, however, evidence in support of the effectiveness of these drugs is lacking. Continued research into the pathophysiology of TMD-related pain and the effectiveness of analgesic treatments for this pain is required.
- 1 January 2010
- Vol. 24 (3) , 255-61
Painful conditioning stimuli of the craniofacial region evokes diffuse noxious inhibitory controls in men and women.
To compare the modulatory effects of tonic mechanical or thermal craniofacial painful conditioning stimuli on pain sensitivity in craniofacial and spinal test sites in healthy men and women. Mechanical and cold headbands were developed and tested on 12 healthy men and 12 age-matched women (mean +/- SEM: 27 +/- 1.5 years). The pressure applied by the mechanical headband around the skull above the eyebrows could be adjusted over time via feedback from a 0 to 10 electronic visual analog scale (VAS) to maintain the pain intensity at a given level for 10 minutes (3 to 7 on VAS). The cold headband consisted of a series of plastic bags filled with antifreeze water having a temperature of approx 3 degrees C. During the 10 minutes of application, the subjects were asked to rate the pain intensity on a 10-cm VAS. Pressure pain thresholds (PPT) were recorded over the right and left masseter muscles (MAR, MAL), right splenius muscle (neck), right elbow (elbow), and right middle finger (finger) by a pressure algometer (1-cm2 area probe). The PPTs at each of the five sites were determined at baseline and during the mechanical or cold-induced pain. The two sessions with mechanical or cold headbands were performed at an interval of 30 minutes. Women had significantly lower absolute PPT values than men at most test sites (Unpaired t-test: P < .027). The mechanical headband caused pain in both men (peak pain mean +/- SEM: 4.7 +/- 0.4 cm) and women (4.9 +/- 0.4 cm) (P = .455). A significant PPT elevation was found at MAR, MAL, neck, and finger in men (11% to 17%; P < .031) and at MAR, MAL, and neck in women (15% to 22%; P < .020) during the mechanical-induced pain. The cold headband caused pain in both men (4.0 +/- 0.4 cm) and women (4.5 +/- 0.4 cm) (P = .285). During the cold-induced pain, a significant PPT elevation was found at all test sites in men (P < .023) and at all sites (P < .021) except for the finger in women. The relative changes in PPT values were not significantly different between men and women at any test site (unpaired t-test: P > .446). This study has documented that mechanical and thermal painful tonic stimuli applied to the craniofacial region can evoke diffuse noxious inhibitory control (DNIC)-like effects in the craniofacial region as well as spinally innervated areas, but without sex differences.
- 1 January 2010
- Vol. 24 (3) , 255-61
Painful conditioning stimuli of the craniofacial region evokes diffuse noxious inhibitory controls in men and women.
To compare the modulatory effects of tonic mechanical or thermal craniofacial painful conditioning stimuli on pain sensitivity in craniofacial and spinal test sites in healthy men and women. Mechanical and cold headbands were developed and tested on 12 healthy men and 12 age-matched women (mean +/- SEM: 27 +/- 1.5 years). The pressure applied by the mechanical headband around the skull above the eyebrows could be adjusted over time via feedback from a 0 to 10 electronic visual analog scale (VAS) to maintain the pain intensity at a given level for 10 minutes (3 to 7 on VAS). The cold headband consisted of a series of plastic bags filled with antifreeze water having a temperature of approx 3 degrees C. During the 10 minutes of application, the subjects were asked to rate the pain intensity on a 10-cm VAS. Pressure pain thresholds (PPT) were recorded over the right and left masseter muscles (MAR, MAL), right splenius muscle (neck), right elbow (elbow), and right middle finger (finger) by a pressure algometer (1-cm2 area probe). The PPTs at each of the five sites were determined at baseline and during the mechanical or cold-induced pain. The two sessions with mechanical or cold headbands were performed at an interval of 30 minutes. Women had significantly lower absolute PPT values than men at most test sites (Unpaired t-test: P < .027). The mechanical headband caused pain in both men (peak pain mean +/- SEM: 4.7 +/- 0.4 cm) and women (4.9 +/- 0.4 cm) (P = .455). A significant PPT elevation was found at MAR, MAL, neck, and finger in men (11% to 17%; P < .031) and at MAR, MAL, and neck in women (15% to 22%; P < .020) during the mechanical-induced pain. The cold headband caused pain in both men (4.0 +/- 0.4 cm) and women (4.5 +/- 0.4 cm) (P = .285). During the cold-induced pain, a significant PPT elevation was found at all test sites in men (P < .023) and at all sites (P < .021) except for the finger in women. The relative changes in PPT values were not significantly different between men and women at any test site (unpaired t-test: P > .446). This study has documented that mechanical and thermal painful tonic stimuli applied to the craniofacial region can evoke diffuse noxious inhibitory control (DNIC)-like effects in the craniofacial region as well as spinally innervated areas, but without sex differences.
- 1 January 2010
- Vol. 24 (4) , 350-60
Interstitial glutamate concentration is elevated in the masseter muscle of myofascial temporomandibular disorder patients.
To determine if myofascial temporomandibular disorder (TMD) pain patients have elevated interstitial concentrations of glutamate in the masseter muscle. Thirteen patients (3 men, 10 women) diagnosed with myofascial TMD pain and 10 (2 men, 8 women) age-matched healthy controls participated in a single microdialysis session. Microdialysis was performed in the patients in the most painful point of the masseter muscle, while in the healthy subjects a standardized point in the muscle was chosen. Two microdialysis samples were collected over 40-minute epochs. A blood sample was also taken for analysis of plasma glutamate concentration. Numeric rating scale (NRS) scores of pain intensity and unpleasantness, McGill Pain Questionnaire data, pain drawing areas, pressure pain thresholds, pressure pain tolerances, maximum voluntary bite force, and maximum voluntary mouth opening were collected as secondary measurements. The median concentration of glutamate in the masseter muscle of the myofascial TMD pain patients (7.5 ± 2.6 ΜM) was significantly higher (P < .023, Mann-Whitney test) than the concentration in healthy controls (0.5 ± 0.4 ΜM). There were, however, no significant correlations between glutamate concentrations in the masseter muscle and NRS pain scores. Plasma concentrations of glutamate were similar in patients and healthy controls. The present study demonstrates a marked increase in interstitial glutamate concentration in the masseter muscle of myofascial TMD pain patients. These novel findings suggest that peripheral glutamate could be involved in the pathophysiology of myofascial TMD pain.
- 1 January 2010
- Vol. 24 (4) , 350-60
Interstitial glutamate concentration is elevated in the masseter muscle of myofascial temporomandibular disorder patients.
To determine if myofascial temporomandibular disorder (TMD) pain patients have elevated interstitial concentrations of glutamate in the masseter muscle. Thirteen patients (3 men, 10 women) diagnosed with myofascial TMD pain and 10 (2 men, 8 women) age-matched healthy controls participated in a single microdialysis session. Microdialysis was performed in the patients in the most painful point of the masseter muscle, while in the healthy subjects a standardized point in the muscle was chosen. Two microdialysis samples were collected over 40-minute epochs. A blood sample was also taken for analysis of plasma glutamate concentration. Numeric rating scale (NRS) scores of pain intensity and unpleasantness, McGill Pain Questionnaire data, pain drawing areas, pressure pain thresholds, pressure pain tolerances, maximum voluntary bite force, and maximum voluntary mouth opening were collected as secondary measurements. The median concentration of glutamate in the masseter muscle of the myofascial TMD pain patients (7.5 ± 2.6 ΜM) was significantly higher (P < .023, Mann-Whitney test) than the concentration in healthy controls (0.5 ± 0.4 ΜM). There were, however, no significant correlations between glutamate concentrations in the masseter muscle and NRS pain scores. Plasma concentrations of glutamate were similar in patients and healthy controls. The present study demonstrates a marked increase in interstitial glutamate concentration in the masseter muscle of myofascial TMD pain patients. These novel findings suggest that peripheral glutamate could be involved in the pathophysiology of myofascial TMD pain.
- 1 January 2010
- Vol. 24 (4) , 398-407
Effects of low-dose intramuscular ketorolac on experimental pain in the masseter muscle of healthy women.
To investigate the effect of a low dose of intramuscular (im) ketorolac compared with lidocaine (LA) in a double-blinded, randomized, and controlled trial. Twelve healthy women participated in three sessions and received two injections into their right masseter muscle per session. The first injections contained hypertonic saline (HS, 5% in 0.2 mL) to induce muscle pain. The second injections were given 30 minutes later and contained, together with HS, either ketorolac (3 mg in 0.2 mL), LA (2% lidocaine in 0.2 ml), or HS alone (control). HS-evoked pain intensity was scored on a 0 to 10 electronic visual analog scale (VAS) measuring peak, duration, and area under the curve (AUC). Pressure pain thresholds (PPT), pressure pain tolerance levels (PPTOL), and pain on palpation (POP) were determined bilaterally on the masseter muscle before and 5, 15, and 25 minutes after the injections. Maximum jaw opening (MJO) was measured at baseline and every 10 minutes after. McGill Pain Questionnaire (MPQ) scores and the extent of the HS-evoked pain (pain drawings) were recorded at baseline, 2 minutes after the first and second injections, and every 10 minutes during the entire experimental session. There were no differences between the three sessions in HS-evoked pain measures from the first injection (P > .05). During the second injection, HS + LA demonstrated significantly lower VAS peak, duration, and AUC scores than control and HS + ketorolac (P < .001). In the HS + ketorolac session, the VAS AUC was significantly lower than in the control session (P < .005). The sessions had no main effect on PPT, PPTOL, POP, MJO, or pain drawings (P > .05). A low dose of im ketorolac has a significant and immediate analgesic effect on HS-evoked jaw muscle pain but significantly less than LA. A local anesthetic-like effect may be the underlying mechanism.
- 1 January 2010
- Vol. 24 (4) , 398-407
Effects of low-dose intramuscular ketorolac on experimental pain in the masseter muscle of healthy women.
To investigate the effect of a low dose of intramuscular (im) ketorolac compared with lidocaine (LA) in a double-blinded, randomized, and controlled trial. Twelve healthy women participated in three sessions and received two injections into their right masseter muscle per session. The first injections contained hypertonic saline (HS, 5% in 0.2 mL) to induce muscle pain. The second injections were given 30 minutes later and contained, together with HS, either ketorolac (3 mg in 0.2 mL), LA (2% lidocaine in 0.2 ml), or HS alone (control). HS-evoked pain intensity was scored on a 0 to 10 electronic visual analog scale (VAS) measuring peak, duration, and area under the curve (AUC). Pressure pain thresholds (PPT), pressure pain tolerance levels (PPTOL), and pain on palpation (POP) were determined bilaterally on the masseter muscle before and 5, 15, and 25 minutes after the injections. Maximum jaw opening (MJO) was measured at baseline and every 10 minutes after. McGill Pain Questionnaire (MPQ) scores and the extent of the HS-evoked pain (pain drawings) were recorded at baseline, 2 minutes after the first and second injections, and every 10 minutes during the entire experimental session. There were no differences between the three sessions in HS-evoked pain measures from the first injection (P > .05). During the second injection, HS + LA demonstrated significantly lower VAS peak, duration, and AUC scores than control and HS + ketorolac (P < .001). In the HS + ketorolac session, the VAS AUC was significantly lower than in the control session (P < .005). The sessions had no main effect on PPT, PPTOL, POP, MJO, or pain drawings (P > .05). A low dose of im ketorolac has a significant and immediate analgesic effect on HS-evoked jaw muscle pain but significantly less than LA. A local anesthetic-like effect may be the underlying mechanism.
- 1 September 2009
- Published by American Physiological Society in Journal of Neurophysiology
- Vol. 102 (3) , 1551-1559
TNFα Mechanically Sensitizes Masseter Muscle Afferent Fibers of Male Rats
Behavioral evidence in rats indicates that injection of tumor necrosis factor alpha (TNFα) into skeletal muscle results in a prolonged mechanical sensitization without gross inflammation. To investigate whether a peripheral mechanism could underlie this effect, in the present study, TNFα (1 or 0.1 μg) was injected into the rat masseter muscle to assess its effect on the excitability and mechanical threshold (MT) of muscle nociceptors as well as on inflammation. Expression of TNFR1 (P55 receptors) and TNFR2 (P75 receptors) by the masseter muscle and trigeminal ganglion neurons that innervate that muscle was determined by Western blot and immunohistochemistry, respectively. The Evans blue dye technique was used at the end of the TNFα experiments to assess for plasma protein extravasation. In subsequent experiments to confirm the involvement of receptor activation in TNFα-induced effects, P55 or P75 receptor antibody was co-injected with TNFα. Intramuscular injection of 1 μg TNFα did not excite nociceptors but did significantly decrease MT compared with vehicle control. There was no evidence of gross inflammation 3 h after injection of TNFα. Co-injection of TNFα with P55 or P75 receptor antibodies attenuated TNFα-induced mechanical sensitization. P55 and P75 receptors were expressed by 29 and 62% of masseter nociceptors, respectively. These findings indicate that TNFα induces mechanical sensitization of masseter nociceptors that is mediated through activation of peripheral P55 and P75 receptors. These results support the hypothesis that a peripheral receptor mechanism could contribute to TNFα-induced noninflammatory mechanical sensitization of skeletal muscle previously reported in behaving rats.
- 1 September 2009
- Published by American Physiological Society in Journal of Neurophysiology
- Vol. 102 (3) , 1551-1559
TNFα Mechanically Sensitizes Masseter Muscle Afferent Fibers of Male Rats
Behavioral evidence in rats indicates that injection of tumor necrosis factor alpha (TNFα) into skeletal muscle results in a prolonged mechanical sensitization without gross inflammation. To investigate whether a peripheral mechanism could underlie this effect, in the present study, TNFα (1 or 0.1 μg) was injected into the rat masseter muscle to assess its effect on the excitability and mechanical threshold (MT) of muscle nociceptors as well as on inflammation. Expression of TNFR1 (P55 receptors) and TNFR2 (P75 receptors) by the masseter muscle and trigeminal ganglion neurons that innervate that muscle was determined by Western blot and immunohistochemistry, respectively. The Evans blue dye technique was used at the end of the TNFα experiments to assess for plasma protein extravasation. In subsequent experiments to confirm the involvement of receptor activation in TNFα-induced effects, P55 or P75 receptor antibody was co-injected with TNFα. Intramuscular injection of 1 μg TNFα did not excite nociceptors but did significantly decrease MT compared with vehicle control. There was no evidence of gross inflammation 3 h after injection of TNFα. Co-injection of TNFα with P55 or P75 receptor antibodies attenuated TNFα-induced mechanical sensitization. P55 and P75 receptors were expressed by 29 and 62% of masseter nociceptors, respectively. These findings indicate that TNFα induces mechanical sensitization of masseter nociceptors that is mediated through activation of peripheral P55 and P75 receptors. These results support the hypothesis that a peripheral receptor mechanism could contribute to TNFα-induced noninflammatory mechanical sensitization of skeletal muscle previously reported in behaving rats.